

Food & Function

Linking the chemistry and physics of food with health and nutrition

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: W. Xu, L. Lin, A. Liu, T. Zhang, S. Zhang, Y. Li, J. Chen, Z. Gong, Z. Liu and W. Xiao, *Food Funct.*, 2020, DOI: 10.1039/D0FO01069C.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 L-Theanine affects intestinal mucosal immunity by
2 regulating short-chain fatty acid metabolism under dietary
3 fiber feeding

4 Wei Xu,^{a,b,c} Ling Lin,^{a,b,c} An Liu,^{a,b,c} Tuo Zhang,^{a,b,c} Sheng Zhang,^{a,b,c} Yinhua Li,^{a,b,c}
5 Jinhua Chen,^{a,b,c} Zhihua Gong,^{a,b,c} Zhonghua Liu^{a,b,c,*} Wenjun Xiao^{a,b,c,*}

6 ^aKey Lab of Tea Science of Ministry of Education, Hunan Agricultural University,
7 Changsha, Hunan 410128, China

8 ^bNational Research Center of Engineering Technology for Utilization of Botanical
9 Functional Ingredients, Hunan Agricultural University, Changsha, Hunan 410128,
10 China

11 ^cHunan Agricultural University, Hunan Collaborative Innovation Center for
12 Utilization of Botanical Functional Ingredients, Changsha, Hunan 410128, China

13 * Corresponding authors. Tel.: +86073184635304; Fax: +86073184635306. E-mail
14 address: larkin_liu@163.com(Z. Liu), xiaowenjun88@sina.com (W. Xiao)

15 **Abstract:** To investigate the effects of L-Theanine (LTA) on intestinal mucosal
16 immunity and the regulation of short-chain fatty acid (SCFA) metabolism under dietary
17 fiber feeding, a 28-day feeding experiment was performed in Sprague-Dawley rats. The
18 results show that LTA increased the proportion of *Prevotella*, *Lachnospira*, and
19 *Ruminococcus* while increasing the total SCFA, acetic acid, propionic acid, and butyric
20 acid contents in the feces. LTA also increased IgA, IgE, and IgG levels in the ileum,
21 and increased villi height and crypt depth. Moreover, LTA upregulated the mRNA and
22 protein expression of acetyl-CoA carboxylase 1, sterol element-binding protein 1c, fatty
23 acid synthase, and 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver,
24 while downregulating the expression of glucose-6-phosphatase and
25 phosphoenolpyruvate carboxykinase 1 in the colon. Our study suggests that LTA can
26 affect intestinal mucosal immunity by regulating SCFA metabolism under dietary fiber
27 feeding.

28

29 **Introduction**

30 With increasing global living standards, high-fat and high-protein diets, which can
31 cause metabolic disorders or metabolic syndrome, have become more common.¹
32 Meanwhile, dietary fiber intake is an important factor in human health that functions to

33 prevent cardiovascular and cerebrovascular diseases, such as hyperlipidemia,
34 hyperglycemia, and atherosclerosis.² Due to the difficulty associated with digesting and
35 absorbing fiber in the small intestine, it can be fermented by gut microbiota, such as
36 *Prevotella*, *Lachnospira*, and *Ruminococcus*, as well as other microbiota in the colon,
37 to produce short-chain fatty acids (SCFAs).^{3, 4}

38 SCFAs are volatile fatty acids that primarily include acetic acid, propionic acid,
39 and butyric acid.⁵ Acetic acid is absorbed by colonic epithelial cells and is transported
40 to the liver as a metabolic substrate involved in the synthesis of cholesterol (TC).⁶
41 Acetic acid reacts with acetyl-CoA carboxylase 1 (ACC1) to form acetyl-CoA (CoA),
42 and participates in the synthesis of fatty acids through the catalysis of fatty acid
43 synthase (FASN).⁷ Fatty acids then synthesize triglycerides (TG) via the catalysis of
44 mitochondrial glycerol-3-phosphate acyltransferase and diacylglycerol acyltransferase
45 for storage in lipid droplets or processing into low-density lipoproteins.⁸ This process
46 is regulated by sterol element-binding protein 1c (SREBP-1C), sterol element-binding
47 protein 2 (SREBP-2), and low-density lipoprotein receptor (LDLR).⁹ Moreover, 3-
48 hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is a key rate-limiting
49 enzyme in the first steps of TC synthesis from acetyl-CoA, which regulates the process
50 of mevalonate synthesis from acetyl-CoA.¹⁰ Alternatively, propionic acid is absorbed
51 by the colonic epithelium and is formed by the action of propionyl-CoA carboxylase
52 and methylmalonyl-CoA isomerase to produce succinyl-CoA. Succinyl-CoA enters the
53 tricarboxylic acid cycle to form oxaloacetate, which participates in gluconeogenesis.¹¹
54 Propionic acid can also inhibit cholesterol synthesis by regulating the expression of
55 HMGCR.¹² Meanwhile, oxaloacetate forms phosphoenolpyruvate under the catalysis
56 of phosphoenolpyruvate carboxylase, which reacts to produce glucose-6-phosphate.¹³
57 Glucose-6-phosphate is hydrolyzed by glucose-6-phosphatase (G6PC) to form
58 glucose.¹⁴ Glucose can enter the liver under the action of glucose transporter 2 (GLUT2)
59 and can be phosphorylated by glucokinase to produce glucose 6-phosphate, which
60 enters the glycolysis or glycogen synthesis pathways. Phosphofructokinase (PFK) and
61 glycogen synthase kinase 3 (GSK-3 β) are key enzymes regulating glycolysis and
62 glycogen synthesis.¹⁵ Finally, butyric acid and propionic acid participate in
63 gluconeogenesis after being absorbed by colonic epithelial cells in the same form.

64 Moreover, butyric acid participates in colonic epithelial energy metabolism.¹⁶

65 SCFAs are regarded as mediators of communication between the intestinal
66 microbiome and the immune system. The signals they produce are transferred to various
67 targets, including immune cells via free fatty acid receptors, which belong to the family
68 of G protein-coupled receptors.¹⁷ A previous study reported that SCFAs that transmit
69 information between the gut microbiota and the immune system could improve
70 intestinal immunity.¹⁸ Moreover, the intestinal mucosal epithelium can enable
71 coagulation and adherence of bacteria by regulating immunoglobulin A (IgA) and
72 immunoglobulin G (IgG) levels.^{19,20} This prevents bacteria from contacting the surface
73 of intestinal epithelial cells and invading the host.²¹ SCFA supplementation can
74 promote the secretion of IgA and IgG in the intestinal mucosal. Hence, SCFAs can
75 simultaneously provide energy to colonic epithelial cells, promote intestinal
76 development, improve the mucosal barrier, maintain the integrity of the intestinal
77 mucosal barrier, and protect the intestinal morphology.²² Indeed, SCFA metabolism can
78 also improve intestinal mucosal immunity. ACC1 is crucial in SCFA metabolism.
79 Meanwhile, a previous study has shown that T-cell-specific targeting of the ACC1, a
80 major checkpoint controlling fatty acid synthesis, impaired intestinal T helper type 1
81 and T helper type 17 responses by limiting CD4⁺ T-cell expansion and infiltration into
82 the lamina propria in murine models of colitis and infection-associated intestinal
83 inflammation.²³ It suggests that ACC1 is an important protein for the metabolic immune
84 modulation of T-cell-driven intestinal inflammatory responses.

85 As a new food ingredient, L-theanine (LTA), a characteristic non-protein amino
86 acid, has demonstrated favorable effects for improving intestinal mucosal immunity. In
87 fact, LTA has been shown to improve the intestinal structure of ducks by elevating
88 jejunum villus height and villus height to crypt depth ratio, as well as improving non-
89 specific immunity in the intestinal mucosal.²⁴ Meanwhile, LTA, which is metabolized
90 to glutamic acid, may act as a glutamic acid donor *in vivo*, thereby increasing the
91 synthesis of glutathione and enhancing IgG levels.²⁵ Further, ethylamine, another
92 metabolite of LTA, significantly reduces the ability of gluten proteins to stimulate a T-
93 cell-mediated immune response in the intestines.²⁶ Additionally, LTA is essential for
94 regulating glycolipid metabolism,²⁷ which relates to SCFA metabolism. However, the

95 mechanism by which LTA regulates SCFA metabolism and intestinal mucosal immune
96 functions via SCFA metabolism has not yet been examined. In this study, we, therefore,
97 sought to examine the effects of LTA on intestinal mucosal immunity by regulating
98 SCFA metabolism under dietary fiber feeding in rats. The results from this investigation
99 provide a basis for improving the intestinal mucosal immune function, promoting the
100 use of diversified food nutrition intervention, and supporting the utilization of LTA in
101 functional food.

102

103 **Experimental**

104 **Chemicals and reagents**

105 Resistant starch II (Brand name: Fibersol-2) was purchased from Shanghai
106 Youshan Biotech Co., Ltd. (Shanghai, China). LTA (purity $\geq 98\%$) was purchased from
107 Hunan Sunfull Biotech Co., Ltd. (Changsha, China). LTA is extracted from an aqueous
108 solution of green tea via flocculation and precipitation to remove protein. Extra tea
109 pigment is then adsorbed by macroporous resin and purified by cation exchange resin
110 732 to obtain high purity LTA.

111 Kits for assessing IgA, IgE, and IgG, total SCFAs, acetic acid, propionic acid, and
112 butyric acid contents were purchased from Shanghai Zcibio Technology Co., Ltd.
113 (Shanghai, China). Assay kits for evaluating TC, TG, high-density lipoprotein
114 cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were purchased
115 from the Institute of Jiancheng Bioengineering (Nanjing, China).

116 The E.Z.N.A.® total RNA kit (R6688-01) was purchased from Omega Bio-tek,
117 Inc. (Norcross, GA, USA). FastKing gDNA dispelling RT SuperMix (KR118) and
118 SYBR green (FP209) were purchased from Beijing Tiangen Biotech Co., Ltd. (Beijing,
119 China). The total protein extraction radioimmunoprecipitation assay kit and
120 bicinchoninic acid kit were purchased from Beyotime Institute of Biotechnology
121 (Jiangsu, China). Antibodies against β -actin (66009-1-Ig), FASN (10624-2-AP),
122 HMGCR (13533-1-AP), GLUT2 (20436-1-AP), PCK1 (16754-1-AP), and PFKM
123 (55028-1-AP) were obtained from Proteintech (Rosemont, IL, USA). Antibodies
124 against ACC1 (ab20453), G6PC (ab133964), SGLT1 (ab14686), LDLR (ab52818),
125 SREBP-1c (ab28481), and SREBP-2 (ab28482) were obtained from Abcam
126 (Cambridge, UK).

127

128 Animals and experimental design

129 All experimental procedures and animal care were performed in strict accordance
130 with the NIH guidelines for the care and use of laboratory animals (NIH Publication
131 No. 85-23 Rev. 1985). Protocols were approved by the Ethics Committee of Hunan
132 Agriculture University (registry number: 015063506, Changsha, China). Male specific
133 pathogen-free Sprague-Dawley rats (aged 4 weeks) were purchased from Hunan SJA
134 Laboratory Animal Co., Ltd. (Changsha, China) and housed at the Tea Institution of
135 Hunan Agricultural University under conditions of controlled temperature ($25^{\circ}\text{C} \pm 2^{\circ}\text{C}$)
136 and humidity (50–70%) and maintained under a 12-h light/dark cycle. All rats had ad
137 libitum access to food and water. They were acclimatized for one week before the
138 commencement of the experiments.

139 Fifty healthy, male, pathogen-free Sprague-Dawley rats were randomly
140 categorized into five groups according to their body weights ($n = 10$ per group): normal
141 feeding group (Control A), dietary fiber feeding group (Control B), LTA 500, LTA
142 middle-weight group 300, and LTA 100. The rats in the LTA500, LTA300, and
143 LTA100 groups were administered 500, 300, and 100 mg/kg of LTA, respectively. Rats
144 in the control groups were administered physiological saline. LTA was adjusted to
145 specific concentrations using physiological saline. The administered volume was fixed
146 at 1 mL/100 g body weight. Meanwhile, rats in the Control B, LTA500, LTA300, and
147 LTA100 groups were fed with dietary fiber feed containing 2% resistant starch II, 18%
148 protein (24.7% energy supply ratio), 58% carbohydrates (67.1% energy supply ratio),
149 4.8% lipids (8.2% energy supply ratio) and 3% minerals. All rats were administered
150 these agents by gavage continuously for 28 days, fasted for 12 h after the last gavage,
151 and then sacrificed by sodium pentobarbital injection. The liver, ileum, colon, and feces
152 were dissected from each rat and stored at -80°C until use.

153

154 Biochemical analysis

155 Blood was collected from the abdominal aorta, and the serum fraction was
156 separated by centrifugation at $3000 \text{ r} \cdot \text{min}^{-1}$ for 10 min. The contents of blood glucose,
157 TC, TG, LDL-C, and HDL-C were measured using spectrophotometric kits in

158 accordance with the manufacturer's instructions.

View Article Online
DOI: 10.1039/D0FO01069C

159 The feces were centrifuged at $1000\text{ g}\cdot\text{min}^{-1}$ for 20 min, and the supernatant was
160 collected. The total SCFAs, acetic acid, propionic acid, and butyric acid contents were
161 measured using spectrophotometric kits in accordance with the manufacturer's
162 instructions.

163

164 Evaluation of intestinal tissue section

165 The rat duodenum, jejunum, and ileum were paraffin-embedded, sectioned, and
166 stained with hematoxylin and eosin (HE). The intestinal villus height and crypt depth
167 were measured in 100 fields of view for each group and photographed. The entire field
168 of vision was filled to ensure that the background light in each photo was consistent
169 between images. Villus height (mm) and crypt depth (mm) were measured in the images
170 using Image-Pro Plus 6.0 software.

171

172 Determination of gut microbiota

173 The V3-V4 variable region of bacteria 16S rDNA in rat intestinal feces was
174 amplified by polymerase chain reaction (PCR). The primers used for amplification were
175 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-
176 GGACTACHVGGGTWTCTAAT-3'). Total DNA from feces was isolated using the
177 FastDNA® spin kit for soil according to the manufacturer's instructions. To quantify
178 gene expression, the extracted DNA was subjected to qRT-PCR in a total reaction
179 volume of 20 μL containing 4 μL FastPfu buffer, 2 μL dNTPs, 0.8 μL of forward and
180 reverse primers, 0.4 μL FastPfu polymerase, 0.2 μL BSA, 10 ng template DNA, and
181 8.8 μL ddH₂O. Reactions were performed on an ABI 7500 Fast real-time PCR system
182 (Applied Biosystems, Foster City, CA, USA). The protocol was as follows:
183 denaturation at 95 °C for 3 min, followed by 30 cycles at 95 °C for 30 s, and
184 amplification at 72 °C for 45 s. For the melting curve analysis, the temperature was
185 increased from 60 °C to 72 °C. The PCR products were purified using an AxyPrep
186 DNA gel extraction kit, according to the manufacturer's instructions. The fragments
187 were sequenced using the Illumina's Miseq PE300 platform.

188 Regarding the Trimmomatic software for quality control of the original

189 sequencing and FLASH software for splicing, (1) a 50 bp window was set. If the
190 average quality value in the window was less than 20, all sequences at the back of the
191 base from the front of the window were cut off, and after removing the quality control,
192 the length of the sequence was less than 50 bp; (2) according to the overlapping base
193 overlap, the two ends of the sequence were spliced, the maximum mismatch rate
194 between overlaps during splicing was 0.2, and the length had to be greater than 10 bp;
195 (3) according to the beginning and end of the sequence, the barcodes and primers at
196 both ends split the sequence into each sample. The barcodes had to be matched exactly.
197 The primers allowed 2 base mismatches and removed sequences with ambiguous bases.

198 The UPARSE software (version 7.1) was used to perform OTU clustering of
199 sequences based on 97% similarity and remove single sequences and chimeras in the
200 clustering process, using the RDP classifier to classify and annotate each sequence,
201 compare the Silva database (SSU123), and set the comparison threshold to 70%.

202

203 Real-time quantitative PCR

204 Total RNA from liver and colon tissues were isolated using the E.Z.N.A.® Total
205 RNA kit I according to the manufacturer's instructions. cDNA was synthesized using
206 FastKing gDNA dispelling RT SuperMix according to the manufacturer's instructions
207 and stored at -20 °C until quantitative reverse transcription (qRT)-PCR was performed.

208 Rat β -actin endogenous reference gene primer and oligonucleotide primers were
209 synthesized by Tsingke Bioengineering Co., Ltd. (Beijing, China). The details of these
210 primers are listed in Table 1. To quantify gene expression, the synthesized cDNA was
211 subjected to qRT-PCR in a total reaction volume of 20 μ L according to SYBR green
212 manufacturer's instructions (Beijing Tiangen Biotech Co.). Briefly, the qRT-PCR
213 reaction mix was comprised of 10 μ L SYBR green, 2 μ L cDNA template, 0.4 μ L each
214 of forward and reverse primers, 0.4 μ L ROX Reference Dye II (50 \times), and 6.8 μ L
215 sterilized water. Reactions were performed on an ABI 7500 Fast real-time PCR system
216 (Applied Biosystems, Foster City, CA, USA). The protocol included denaturation at 95
217 °C for 30 min, followed by 40 cycles at 95 °C for 5 s, and amplification at 60 °C for 15
218 s. For melting curve analysis, the temperature was increased from 60 °C to 95 °C. β -
219 Actin was used as a housekeeping gene to normalize the transcript levels of target genes.

220 The threshold cycle (CT) value of each reaction was determined at the end of the qRT-PCR
221 PCR run. The change in transcriptional level of each target gene, normalized to the
222 expression level of β -actin, was calculated using the following formula: relative mRNA
223 level of target gene = $2^{-\Delta\Delta CT}$, where $\Delta\Delta CT = (CT \text{ Target} - CT \beta\text{-actin}) \text{ treatment} -$
224 $(CT \text{ Target} - CT \beta\text{-actin}) \text{ control}$.

225

226 Western blotting

227 Total proteins from the liver and colon tissues were isolated using lysis buffer;
228 protein concentration was estimated using a BCA protein assay kit (Beyotime Institute
229 of Biotechnology Inc.), and western blotting was performed as reported by Gong et al.²⁸

230

231 Statistical analysis

232 All statistical analyses were performed using the SPSS software (version 24.0;
233 SPSS, Inc., Chicago, IL, USA). Differences among the treated groups were compared
234 by one-way analysis of variance with the least significant difference post hoc test. The
235 results are expressed as the mean \pm standard error (SE). $P < 0.05$ was considered to be
236 statistically significant.

237

238 Results

239 Effects of L-theanine on total SCFA, acetic acid, propionic acid, butyric acid, and
240 intestinal gut microbiota content in rat feces under dietary fiber feeding

241 Total SCFAs, propionic acid, and butyric acid contents were higher in the Control
242 B group compared to the Control A group ($P < 0.05$; Table 2). The values were also
243 significantly higher in the LTA300 and LTA500 groups than in the Control B group (P
244 < 0.01). The proportions of *Prevotella* and *Ruminococcus* were higher in the Control B
245 group than in the Control A group ($P < 0.05$), as was the proportion of *Lachnospira* (P
246 < 0.01 ; Table 2). Meanwhile, the proportion of *Ruminococcus* was higher in the
247 LTA100 group ($P < 0.05$) compared to the Control B group, and the proportions of
248 *Prevotella*, *Lachnospira*, and *Ruminococcus* were significantly higher in the LTA300
249 and LTA500 groups ($P < 0.01$) compared to the Control B group. Alternatively, the
250 proportion of *Helicobacter* was lower in Control B rats compared to Control A ($P <$
251 0.05), while it was significantly lower in the LTA100, LTA300 and LTA500 groups

252 compared to Control B ($P < 0.01$).

253

254 Effects of LTA on the expression of key factors involved in acetic acid metabolism in
255 the liver under dietary fiber feeding

256 The mRNA expression of ACC1, SREBP-1c, SREBP-2, FASN, HMGCR, and
257 LDLR was significantly lower in Control B rats compared to that in Control A rats (P
258 < 0.01 ; Table 3). However, the expression of SREBP-1c and HMGCR was higher in
259 the LTA100 group than that in the Control B group ($P < 0.05$). Similarly, the mRNA
260 expression of LDLR was higher in the LTA300 group than that in the Control B ($P <$
261 0.05), and that of SREBP-1c, FASN, and HMGCR was significantly higher in the
262 LTA300 group than that in Control B group ($P < 0.01$). Additionally, the mRNA
263 expression of HMGCR was higher in the LTA500 group than that in Control B ($P <$
264 0.05), and that of ACC1, SREBP-1c, FASN, and LDLR was significantly higher in the
265 LTA500 group than that in Control B ($P < 0.01$).

266 Similar to the mRNA expression, the expression of ACC1, SREBP-1c, SREBP-2,
267 FASN, HMGCR, and LDLR proteins was significantly lower in Control B than in
268 Control A ($P < 0.05$) (Fig. 1). Meanwhile, the expression of ACC1, LDLR, and SREBP-
269 2 was higher in the LTA100 group than that in Control B ($P < 0.05$). The expression of
270 SREBP-1c and HMGCR proteins was significantly higher in the LTA100 group than
271 that in Control B. The expression of FASN, LDLR, SREBP-1c, and SREBP-2 proteins
272 was higher in the LTA300 group than that in Control B ($P < 0.05$). The expression of
273 ACC1 and HMGCR was significantly higher in the LTA300 group than that in Control
274 B ($P < 0.01$). Finally, the expression of ACC1, SREBP-1c, SREBP-2, FASN, HMGCR,
275 and LDLR proteins was significantly higher in the LTA500 group than that in Control
276 B ($P < 0.01$).

277

278 Effects of LTA on the expression of key factors involved in propionate and butyrate
279 acid metabolism in the colon under dietary fiber feeding

280 The protein and mRNA expression of GLUT2, PCK1, G6PC, PFKM, GSK-3 β ,
281 and SGLT1 was significantly higher in Control B than that in Control A ($P < 0.01$)
282 (Figure 1, Table 3). Meanwhile, the mRNA expression of GLUT2, PCK1, G6PC,

283 PFKM, GSK-3 β , and SGLT1 was significantly lower in the LTA100 and LTA300
284 groups than that in Control B ($P < 0.01$). The mRNA expression of GLUT2, PCK1,
285 G6PC, PFKM, and GSK-3 β was lower in the LTA500 group than that in Control B (P
286 < 0.05), and that of SGLT1 was significantly lower in the LTA500 group than that in
287 Control B ($P < 0.01$).

288 Additionally, the protein expression of GLUT2, PCK1, G6PC, PFKM, GSK-3 β ,
289 and SGLT1 was lower in the LTA100 group compared to that in Control B ($P < 0.05$),
290 while, the protein expression of GLUT2, PCK1, G6PC, PFKM, GSK-3 β , and SGLT1
291 was significantly lower in the LTA300 group than that in Control B ($P < 0.01$), and the
292 expression of PCK1, G6PC, PFKM, GSK-3 β , and SGLT1 was lower in the LTA500
293 group than that in Control B ($P < 0.05$).

294

295 Effect of LTA on serum glucose, TC, TG, HDL-C, and LDL-C contents under dietary
296 fiber feeding

297 Blood glucose did not differ between the LTA and control groups (Table 4).
298 However, the LDL-C ($P < 0.05$), TC, and TG ($P < 0.01$) contents were lower in Control
299 B than those in Control A. Moreover, TC and TG were lower in the LTA groups than
300 those in Control B ($P < 0.05$), while HDL-C was higher in the LTA100 and LTA500
301 groups than that in Control B ($P < 0.05$).

302

303 Effect of LTA on ileum immunoglobulin content and intestinal morphology of rats
304 under dietary fiber feeding

305 IgA, IgE, and IgG contents were higher in Control B rats than in the Control A
306 group ($P < 0.05$) (Table 4). However, IgE ($P < 0.05$), IgA, and IgG ($P < 0.01$) contents
307 were higher in the LTA100 group compared to those in Control B. Similarly, IgA, IgE,
308 and IgG contents were significantly higher in the LTA300 group than those in the
309 Control B group ($P < 0.01$), while only IgA and IgG levels were significantly higher in
310 the LTA500 group compared to those in Control B ($P < 0.01$).

311 The villi height and villi height/crypt depth (V/C) in the jejunum, as well as the
312 crypt depth in the duodenum and ileum, were higher in Control B rats compared to the
313 Control A group ($P < 0.05$) (Fig. 2, Table 5). Crypt depth in the jejunum and the ileum

314 villi height were significantly higher in Control B than in Control A ($P < 0.01$).
315 Meanwhile, the villi height, crypt depth, and V/C in the ileum and V/C in the jejunum
316 were higher in the LTA100 group than those in Control B ($P < 0.05$). Similarly, the villi
317 height, crypt depth, and V/C in the ileum, as well as the villi height in the jejunum, were
318 higher in the LTA300 group than those in Control B rats ($P < 0.05$). Finally, the villi
319 height and V/C in the jejunum, as well as the V/C in the ileum were higher in LTA500
320 rats compared to those in the Control B group ($P < 0.05$)

322 Discussion

323 Dietary fiber is the main source of SCFAs, which are produced by gut microbiota
324 fermentation, with *Prevotella*, *Lachnospira*, and *Ruminococcus* serving as the primary
325 microbiota that produces SCFAs. Hence, the type and number of intestinal microbiota
326 members play an important role in SCFA production. A previous study has shown that
327 LTA improves gut microbiota by maintaining the intestinal cell structure and barrier
328 function.²⁹ Our results further indicate that LTA increases the proportion of *Prevotella*,
329 *Lachnospira*, and *Ruminococcus*, which led to the increased levels of SCFAs.
330 Specifically, increases in acetic acid, propionic acid, and butyric acid were observed.
331 Meanwhile, LTA decreased the proportion of *Helicobacter*, which is harmful to
332 intestinal immunity.³⁰

333 Acetic acid is metabolized in the liver, whereas propionic acid and butyric acid are
334 metabolized in the colon.³¹ Acetic acid is used as a raw material to form acetyl-CoA
335 through the action of ACC1. Fatty acids, which form TGs, are synthesized by acetyl-
336 CoA under FASN catalysis; next, TGs are used to synthesize TC under the regulation
337 of SREBP-1C, SREBP-2, and LDLR.³² In our study, LTA upregulated the expression
338 of ACC1 and FASN at the mRNA and protein levels and promoted the formation of
339 fatty acids. As fatty acid levels increased, SREBP-1C, SREBP-2, and LDLR mRNA
340 and protein expressions were upregulated, ultimately leading to increased TC and TG
341 contents. However, Wan et al. showed that adding dietary fiber to feed can significantly
342 reduce the contents of serum TC and TG.³³ This discrepancy may be attributed to the
343 fact that SCFAs are used as energy sources by the body. Our results are in agreement
344 with those of Tan et al., who suggested that the contents of TC and TG are regulated by
345 acetic acid, which affects the expression of SREBP-1C and ACC1.³⁴ Interestingly,

346 Eftychia et al. showed that the normal cholesterol level is 2.84–5.17 mmol/L.
347 Moreover, low TC levels make it difficult for the body to perform physiological
348 activities. After feeding rats with LTA, endogenous SCFA synthesis was greatly
349 increased, which promoted its energy storage and increased the synthesis of TG and
350 TC; this partially agrees with the results of a previous study showing that increasing
351 dietary fiber effectively increases the TC content.³⁶ Meanwhile, Peng et al. showed that
352 low levels of cholesterol caused upper gastrointestinal bleeding. Then, they further
353 demonstrated that cholesterol not only mediates many important lipid metabolism
354 functions but also maintains normal TC levels, which are essential for numerous
355 physiological functions.³⁷

356 After being absorbed by colonic epithelial cells, propionic acid and butyric acid
357 produce oxaloacetate, which involves a series of enzymes. Oxaloacetate initiates the
358 gluconeogenic pathway to form glucose via reactions catalyzed by PCK1 and G6PC.³⁸
359 Glucose can then be transported to various organs for metabolism via the action of
360 GLUT2, followed by glycolysis or glycogen synthesis. In our study, LTA
361 downregulated the expression of G6PC and PCK1 mRNA and protein. Propionic acid
362 and butyric acid can synthesize oxaloacetate or inhibit colon gluconeogenesis.
363 Moreover, glucose can be used in glycogen synthesis and glycolysis via the action of
364 GSK-3 β and PFKM.

365 In our study, LTA increased the levels of TG, TC, HDL-C, and LDL-C, while
366 maintaining normal blood glucose levels by promoting the synthesis of cholesterol
367 through acetic acid metabolism and inhibiting gluconeogenesis through propionic acid
368 and butyric acid metabolism. Cholesterol synthesis and gluconeogenesis are closely
369 related to intestinal mucosal immunity. Wahbi et al. showed that excessive cholesterol
370 synthesis and gluconeogenesis disorders could cause glucose metabolism disorders,
371 while cardiovascular diseases caused by disorders in glucose metabolism are closely
372 related to intestinal mucosal immunity.³⁹ In these disorders, intestinal mucosal
373 immunity and the gut microbiota structure are destroyed, leading to intestinal immune
374 dysfunction and mucosal inflammation. This allows bacteria metabolites to enter the
375 blood circulation, which can cause systemic inflammation as well as cardiovascular and
376 cerebrovascular diseases, resulting in cholesterol and glucose metabolism disorders.⁴⁰

377 Therefore, LTA plays an important role in improving intestinal mucosal immunity by
378 maintaining normal TC and blood glucose levels under conditions of dietary fiber
379 feeding.

380 A previous study revealed that increasing the SCFA concentration can increase
381 IgA and IgG levels.⁴¹ This suggests that SCFAs are an important component of the
382 immune cell membrane. Duan et al. showed that SCFAs are preferentially used by
383 intestinal epithelial cells for energy metabolism and are the primary regulators of cell
384 proliferation and differentiation, thereby providing energy to promote intestinal crypt
385 epithelial cell differentiation and improve the morphology of the duodenum, jejunum,
386 and ileum.⁴² Our results showed that LTA significantly increased the contents of IgA,
387 IgE, and IgG, increased the villi height, crypt depth, and V/C in the duodenum, jejunum,
388 and ileum of rats, and improved intestinal morphology. SCFAs can affect intestinal
389 immune function by regulating inflammatory mediator production and signal
390 transduction, thereby playing an important role in maintaining the intestinal mucosal
391 barrier.⁴³ In this study, LTA can regulate SCFA metabolism; thus, improving intestinal
392 mucosal immunity. However, SCFA metabolism is not the only way to affect intestinal
393 mucosal immunity. Further studies using metabolomics and proteomics are needed to
394 investigate the pathways and mechanisms associated with LTA-induced effects to
395 improve intestinal mucosal immunity by regulating SCFA metabolism.

396

397 **Conclusions**

398 Our results show that LTA regulates the proportion of SCFA-producing gut
399 microbiota, thereby increasing the total SCFA content as well as that of acetic acid,
400 propionic acid, and butyric acid. Moreover, LTA regulates SCFA metabolism and
401 improves intestinal mucosal immune function by improving cholesterol synthesis in the
402 liver and inhibiting gluconeogenesis in the colon under dietary fiber feeding.

403

404 **Conflicts of interest**

405 There are no conflicts to declare.

406

407 **Acknowledgments**

408 This work was supported by The National Natural Science Foundation of China

409 (grant number 31871804), Science and Technology Major Project of Hunan Province,
410 China (grant number 2017NK1020), and Science and Technology Major Project of
411 Changsha, China (grant number kq1804003).

412

413 Abbreviations

414 LTA, L-theanine; SCFAs, short-chain fatty acids; TG, triglycerides; TC, total
415 cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
416 lipoprotein cholesterol; FASN, fatty acid synthase; ACC1, acetyl-CoA carboxylase;
417 SREBP-1c, sterol regulatory element-binding protein-1c; SREBP-2, sterol regulatory
418 element-binding protein-2; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase;
419 LDLR, low-density lipoprotein receptor; GSK-3 β , glycogen synthase kinase 3 β ; PFKM,
420 phosphofructokinase, muscle type; PCK1, phosphoenolpyruvate carboxykinase 1;
421 G6PC, glucose-6-phosphatase catalytic subunit; SGLT1, sodium glucose transporter 1;
422 GLUT2, glucose transporter-2; IgA, Immunoglobulin A; IgE, Immunoglobulin E; IgG,
423 Immunoglobulin G; V/C, height of villi/crypt depth.

424

425 Reference

- 426 1. J. P. Rocha, J. Laster, B. Parag and N. U. Shah, Multiple Health Benefits and Minimal Risks
427 Associated with Vegetarian Diets, *Curr Nutr Rep*, 2019, **8**, 374-381.
- 428 2. D. C. Miketinas, G. A. Bray, R. A. Beyl, D. H. Ryan, F. M. Sacks and C. M. Champagne, Fiber
429 Intake Predicts Weight Loss and Dietary Adherence in Adults Consuming Calorie-Restricted
430 Diets: The POUNDS Lost (Preventing Overweight Using Novel Dietary Strategies) Study, *J Nutr*,
431 2019, **149**, 1742-1748.
- 432 3. X. Qian, Y.-X. Liu, X. Ye, W. Zheng, S. Lv, M. Mo, J. Lin, W. Wang, W. Wang, X. Zhang and M. Lu,
433 Gut microbiota in children with juvenile idiopathic arthritis: characteristics, biomarker
434 identification, and usefulness in clinical prediction, 2020.
- 435 4. W. Zhang, J.-H. Xu, T. Yu and Q.-K. Chen, Effects of berberine and metformin on intestinal
436 inflammation and gut microbiome composition in db/db mice, 2019, **118**, 109131.
- 437 5. T. O. Adebawale, K. Yao and A. O. Oso, Major cereal carbohydrates in relation to intestinal
438 health of monogastric animals: A review, *Anim Nutr*, 2019, **5**, 331-339.
- 439 6. C. Lindquist, B. BjC8rnda, A. Lund, G. Slettom, J. Skorve, O. NygC%rd, A. r. Svardal and R. K.
440 Berge, Increased fatty acid oxidation and mitochondrial proliferation in liver are associated
441 with increased plasma kynurenine metabolites and nicotinamide levels in normolipidemic and
442 carnitine-depleted rats, *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of
443 Lipids*, 2020, **1865**, 158543.
- 444 7. D. J. Morrison and T. Preston, Formation of short chain fatty acids by the gut microbiota and
445 their impact on human metabolism, *Gut microbes*, 2016, **7**, 189-200.

- 446 8. C. Li, C. Cai, X. Zheng, J. Sun and L. Ye, Orientin suppresses oxidized low-density lipoproteins
447 induced inflammation and oxidative stress of macrophages in atherosclerosis, *Biosci*
448 *Biotechnol Biochem*, 2020, **84**, 774-779.
- 449 9. A. Kdekian, M. Alsema, E. M. Van Der Beek, A. Greyling, M. A. Vermeer, D. J. Mela and E. A.
450 Trautwein, Impact of isocaloric exchanges of carbohydrate for fat on postprandial glucose,
451 insulin, triglycerides, and free fatty acid responsesb, 2020.
- 452 10. Y. Gai, Y. Li, Z. Xu and J. Chen, Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels
453 and reduces the gene expression regarding the synthesis of cholesterol and triglycerides,
454 *Fitoterapia*, 2019, **139**, 104393.
- 455 11. Q. Li, H. Zhang, J. Zou, X. Feng and D. Feng, Bisphenol A induces cholesterol biosynthesis in
456 HepG2 cells via SREBP-2/HMGCR signaling pathway, *The Journal of Toxicological Sciences*,
457 2019, **44**, 481-491.
- 458 12. G. Maldini, K. M. Kennedy and M. S. Allen, Temporal effects of ruminal infusion of propionic
459 acid on hepatic metabolism in cows in the postpartum period, *Journal of Dairy Science*, 2019,
460 **102**, 9781-9790.
- 461 13. E. Kaemmerer, P. Kuhn, U. Schneider, M. K. Jeon, C. Klaus, M. Schiffer, D. Weisner, C. Liedtke,
462 J. C. r. Jc\$kel, L. N. Kennes, R.-D. Hilgers, N. Wagner and N. Gassler, Intestinal genetic
463 inactivation of caspase-8 diminishes migration of enterocytes, *World journal of*
464 *gastroenterology*, 2015, **21**, 4499-4508.
- 465 14. D. S. Roseman, T. Khan, F. Rajas, L. S. Jun, K. H. Asrani, C. Isaacs, J. D. Farelli and R. R.
466 Subramanian, G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases
467 Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a, *Mol Ther*, 2018, **26**,
468 814-821.
- 469 15. C. Bian, X. Huang, Z. Hu, S. Ji, M. Yang and H. Ji, Glycogen synthase kinase-3N2 (GSK-3N2) of
470 grass carp (*Ctenopharyngodon idella*): Synteny, structure, tissue distribution and expression in
471 oleic acid (OA)-induced adipocytes and hepatocytes, *Comparative Biochemistry and*
472 *Physiology Part B: Biochemistry and Molecular Biology*, 2020, **241**, 110391.
- 473 16. D. Curtis, K. Bakaya, L. Sharma and S. Bandyopadhyay, Weighted burden analysis of exome-
474 sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for
475 PSEN1 and suggests involvement of the PI3K/Akt/GSK-3N2 and WNT signalling pathways, *Ann*
476 *Hum Genet*, 2020, **84**, 291-302.
- 477 17. W. Ratajczak, E. A. Ry, A. Mizerski, K. Walczakiewicz, O. Sipak and E. s. M. Laszczy,
478 Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs), *Acta*
479 *biochimica Polonica*, 2019, **66**, 1-12.
- 480 18. Y. Holota, T. Dovbynychuk, I. Kaji, I. Vareniuk, N. Dzyubenko, T. Chervinska, L. Zakordonets, V.
481 Stetska, L. Ostapchenko, T. Serhiychuk and G. Tolstanova, The long-term consequences of
482 antibiotic therapy: Role of colonic short-chain fatty acids (SCFA) system and intestinal barrier
483 integrity, *PLoS one*, 2019, **14**, e0220642-e0220642.
- 484 19. W. Wu, M. Sun, F. Chen, A. T. Cao, H. Liu, Y. Zhao, X. Huang, Y. Xiao, S. Yao, Q. Zhao, Z. Liu and
485 Y. Cong, Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response
486 to microbiota which is mediated by GPR43, *Mucosal immunology*, 2017, **10**, 946-956.
- 487 20. K. Wang, H. Cao G Fau - Zhang, Q. Zhang H Fau - Li, C. Li Q Fau - Yang and C. Yang, Effects of
488 *Clostridium butyricum* and *Enterococcus faecalis* on growth performance, immune function,
489 intestinal morphology, volatile fatty acids, and intestinal flora in a piglet model.

- 490 21. T. Teng, F. Gao, W. He, H. Fu, J. Guo, G. Bai and B. Shi, An Early Fecal Microbiota Transfer
491 Improves the Intestinal Conditions on Microflora and Immunoglobulin and Antimicrobial
492 Peptides in Piglets, *Journal of Agricultural and Food Chemistry*, 2020, **68**, 4830-4843.
- 493 22. C. Zhang, C. Wang, K. Chen, X. Zhao and Z. Geng, Effect of l-theanine on growth performance,
494 intestinal development and health, and peptide and amino acid transporters expression of
495 broilers, *Journal of the Science of Food and Agriculture*, 2020, **100**, 1718-1725.
- 496 23. M. R. Casanova, J. o. Azevedo-Silva, L. R. Rodrigues and A. Preto, Colorectal Cancer Cells
497 Increase the Production of Short Chain Fatty Acids by *Propionibacterium freudenreichii*
498 Impacting on Cancer Cells Survival, *Front Nutr*, 2018, **5**, 44-44.
- 499 24. C. Zhang, K. K. Chen, X. H. Zhao, C. Wang and Z. Y. Geng, Effect of l-theanine on the growth
500 performance, immune function, and jejunum morphology and antioxidant status of ducks,
501 *animal*, 2018, **13**, 1145-1153.
- 502 25. S. Kurihara, S. Shibahara, H. Arisaka and Y. Akiyama, Enhancement of antigen-specific
503 immunoglobulin G production in mice by co-administration of L-cystine and L-theanine, *The*
504 *Journal of veterinary medical science*, 2007, **69**, 1263-1270.
- 505 26. M. Ribeiro, S. Lopes, S. Picascia, C. Gianfrani and F. M. Nunes, Reinventing the nutraceutical
506 value of gluten: The case of l-theanine-gluten as a potential alternative to the gluten exclusion
507 diet in celiac disease, *Food chemistry*, 2020, **324**, 126840.
- 508 27. L. Lin, L. Zeng, A. Liu, Y. Peng, D. Yuan, S. Zhang, Y. Li, J. Chen, W. Xiao and Z. Gong, l-Theanine
509 regulates glucose, lipid, and protein metabolism via insulin and AMP-activated protein kinase
510 signaling pathways, *Food & Function*, 2020, **11**, 1798-1809.
- 511 28. Z. Gong, Q. Liu, L. Lin, Y. Deng, S. Cai, Z. Liu, S. Zhang, W. Xiao, S. Xiong and D. Chen, l-Theanine
512 prevents ETEC-induced liver damage by reducing intrinsic apoptotic response and inhibiting
513 ERK1/2 and JNK1/2 signaling pathways, *European Journal of Pharmacology*, 2018, **818**, 184-
514 190.
- 515 29. M. Saeed, X. Yatao, Z. Tiantian, R. Qian and S. Chao, 16S ribosomal RNA sequencing reveals a
516 modulation of intestinal microbiome and immune response by dietary l-theanine
517 supplementation in broiler chickens, *Poult Sci*, 2019, **98**, 842-854.
- 518 30. S. H. Kuo, M. S. Wu, K. H. Yeh, C. W. Lin, P. N. Hsu, L. T. Chen and A. L. Cheng, Novel Insights of
519 Lymphomagenesis of *Helicobacter pylori*-Dependent Gastric Mucosa-Associated Lymphoid
520 Tissue Lymphoma, *Cancers*, 2019, **11**.
- 521 31. R. Bohan, X. Tianyu, Z. Tiantian, F. Ruonan, H. Hongtao, W. Qiong and S. Chao, Gut microbiota:
522 a potential manipulator for host adipose tissue and energy metabolism, *J Nutr Biochem*, 2019,
523 **64**, 206-217.
- 524 32. G. M. Buga, J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M.
525 Navab, S. T. Reddy, G. M. Anantharamaiah and A. M. Fogelman, D-4F reduces EO6
526 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice
527 fed a Western diet, *J Lipid Res*, 2008, **49**, 192-205.
- 528 33. Y. Wan, J. Tang, J. Li, J. Li, J. Yuan, F. Wang and D. Li, Contribution of diet to gut microbiota and
529 related host cardiometabolic health: diet-gut interaction in human health, *Gut Microbes*, 2020,
530 **11**, 603-609.
- 531 34. M. H. Kaulage, S. Bhattacharya and K. Muniyappa, Structural Characterization of i-Motif
532 Structure in the Human Acetyl-CoA Carboxylase, 2018, **19**.
- 533 35. E. Papachatzopoulou, C. Chatzakis, I. Lambrinoudaki, K. Panoulis, K. Dinas, N. Vlahos, A.

- 534 Sotiriadis and M. Eleftheriades, Abnormal fasting, post-load or combined glucose values on
535 oral glucose tolerance test and pregnancy outcomes in women with gestational diabetes
536 mellitus, *Diabetes Res Clin Pract*, 2020, **161**, 108048.
- 537 36. L. Li, M. Pan, S. Pan, W. Li, Y. Zhong, J. Hu and S. Nie, Effects of insoluble and soluble fibers
538 isolated from barley on blood glucose, serum lipids, liver function and caecal short-chain fatty
539 acids in type 2 diabetic and normal rats, *Food and chemical toxicology : an international journal
540 published for the British Industrial Biological Research Association*, 2020, **135**, 110937.
- 541 37. J. Peng, X. Xiao, M. Hu and X. Zhang, Interaction between gut microbiome and cardiovascular
542 disease, *Life Sci*, 2018, **214**, 153-157.
- 543 38. K. H. Lee, E.-S. Jeong, G. Jang, J.-R. Na, S. Park, W. S. Kang, E. Kim, H. Choi, J. S. Kim and S. Kim,
544 Unripe *Rubus coreanus* Miquel Extract Containing Ellagic Acid Regulates AMPK, SREBP-2,
545 HMGCR, and INSIG-1 Signaling and Cholesterol Metabolism In Vitro and In Vivo, *Nutrients*,
546 2020, **12**, 610.
- 547 39. K. Wahbi and D. Furling, Cardiovascular manifestations of myotonic dystrophy, *Trends
548 Cardiovasc Med*, 2020, **30**, 232-238.
- 549 40. F. Gomes, A. M. Marques, O. Nathalie, M. A. Lessa, E. Tibiriçá, M. R. Figueiredo and V. Estado,
550 Microvascular Effects of *Echinodorus grandiflorus* on Cardiovascular Disorders, 2020, **86**, 395-
551 404.
- 552 41. X. Tian, J. Hellman, A. R. Horswill, H. A. Crosby, K. P. Francis and A. Prakash.
- 553 42. Y. Duan, Y. Zhang, H. Dong, Y. Wang and J. Zhang, Effect of the dietary probiotic *Clostridium
554 butyricum* on growth, intestine antioxidant capacity and resistance to high temperature stress
555 in kuruma shrimp *Marsupenaeus japonicus*, *Journal of thermal biology*, 2017, **66**, 93-100.
- 556 43. M. S. Hedemann, P. K. Theil and K. E. Bach Knudsen, The thickness of the intestinal mucous
557 layer in the colon of rats fed various sources of non-digestible carbohydrates is positively
558 correlated with the pool of SCFA but negatively correlated with the proportion of butyric acid
559 in digesta, *Br J Nutr*, 2009, **102**, 117-125.
- 560
561
562
563
564
565
566
567
568
569
570
571
572

573

574

575

Genes	Forward Nucleotide sequence primers (5'- 3')	Reverse Nucleotide sequence primers (5'- 3')	Product Size (bp)
β -actin	TGTCACCAACTGGGACGATA	GGGGTGTGAAGGTCTCAA	165
GLUT2	CACCAGCACATACGACACCAGAC	TGGACACAGACAGAGACCAGAGC	90
PCK1	GCGTGCTGGAGTGGATGTTCG	GTCGATCTCCTCCACCTCCTTCTC	176
G6PC	GAGAAGGCCAAGAGATGGTGTGAG	TTGCGGTACATGCTGGAGTTGAG	131
PFKM	TCGACAATGACTTCTGTGGCACTG	TCTGAGCGGTGGTGGTGTGATGG	153
GSK-3 β	GACAGTGGTGTGGATCAGTTGGTG	GCGATTGCCTCTGGTGGAGTTC	167
SGLT1	TCCCGTATGATCACTGAGTTTGC	GGCAGTTGCTGGGTTCCAT	82
ACC1	CAGCGACCACCTGAAGACACTTG	GCTTCCAGCACCGGCATCAG	84
SREBP-1C	TCTCCTGGAGCGAGCATTGA	CAGTGGTGGTAGCCATGCTG	173
HMGCR	ATGTTGACAAGGCTCTGCTGAAGG	AGCCTGAGCCGTAGGAGAATGC	133
FAS	GTTGCTGCTGCTGTGGACCTC	AGGATCACATTGCCGTGGTACTTG	146
LDLR	ACCTGCCGACCTGACGAA	CCAAGCTGATGCACTCCC	83
SREBP-2	TGGGCGATGAGCTGACTCT	CAAATAGGGA ACTCTCCCAC	195

576

Table 1 Primers of genes for RT-PCR

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592 Table 2 Effects of L-theanine on the content total SCFAs, acetic acid, propionic acid, butyric acid

593 and intestinal microorganisms in rat feces under dietary fiber feeding (n=10)

Group	Total SCFAs (PG/ml)	Acetic acid (PG/ml)	Propionic acid (PG/ml)	Butyric acid (PG/ml)	<i>Prevotella</i> (%)	<i>Lachnospira</i> (%)	<i>Ruminococcus</i> (%)	<i>Helicobacter</i> (%)
Control A	312.17±4.20	150.23±0.56	91.98±1.23	54.36±2.25	35.52	7.17	1.75	4.21
Control B	333.23±4.00*	150.14±1.11	102.33±0.98*	58.45±1.02*	25.98*	13.75**	2.35*	3.22
LTA100	361.54±9.16##	166.64±1.56#	117.52±2.11#	65.10±0.81#	42.58##	16.37##	2.87#	2.95#
LTA300	377.77±5.79##	177.54±1.63##	129.21±1.44#	69.09±1.11##	49.52##	18.33##	3.56##	2.22##
LTA500	442.87±5.76##	210.14±1.87##	141.12±1.36##	85.63±2.34##	50.14##	20.32##	4.67##	1.76##

594 Note: Compared with Control A, *: $P < 0.05$, **: $P < 0.01$; Compared with Control B, #: $P <$ 595 0.05 , ##: $P < 0.01$; the same as follows

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

View Article Online

DOI: 10.1039/D0FO01069C

624 Table 3 Effects of LTA on expression of key mRNA involved in acetic acid metabolism in liver
 625 and propionate and butyrate acid metabolism in colon under dietary fiber feeding in rats (n=10)

Group	ACC1	SREBP -1c	SREBP -2	LDLR	FASN	HMGCR	GLUT2	PCK1	G6PC	PFKM	GSK -3 β	SGLT1
Control	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
A	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00
Control	0.65	0.18	0.18	0.35	0.04	0.18	1.92	1.78	1.95	2.15	2.08	2.25
B	±0.12**	±0.03**	±0.02**	±0.09**	±0.01**	±0.01**	±0.05**	±0.08**	±0.03**	±0.03**	±0.02**	±0.05**
LTA	0.74	0.27	0.17	0.36	0.27	0.55	1.42	1.47	1.48	1.66	1.63	1.51
100	±0.03	±0.03#	±0.01	±0.11	±0.01##	±0.14#	±0.02##	±0.02##	±0.03##	±0.09##	±0.03##	±0.01##
LTA	0.75	0.40	0.16	0.62	0.67	0.57	1.31	1.32	1.39	1.49	1.52	1.39
300	±0.09	±0.06##	±0.02	±0.03#	±0.04##	±0.10##	±0.03##	±0.05##	±0.02##	±0.01##	±0.02##	±0.01##
LTA	0.92	0.34	0.14	0.78	0.44	0.44	1.61	1.62	1.76	1.83	1.80	1.32
500	±0.08##	±0.02##	±0.02	±0.06##	±0.05##	±0.07#	±0.01#	±0.01#	±0.03#	±0.03#	±0.02#	±0.03##

626

627 Table 4 Effects of L-theanine on immunoglobulin content in ileum and blood glucose, TG, TG
 628 HDL-C, and LDL-C content in serum under dietary fiber feeding in rats (n=10)

Group	IgA (ug/g)	IgE (ug/g)	IgG (mg/g)	Blood glucose (mmol·L ⁻¹)	TG (mmol·L ⁻¹)	TC (mmol·L ⁻¹)	HDL-C (mmol·L ⁻¹)	LDL-C (mmol·L ⁻¹)
Control A	2582.97±89.18	165.52±7.88	80.75±3.51	4.68±0.12	0.87±0.06	2.97±0.02	0.34±0.03	0.24±0.02
Control B	3079.97±48.31*	199.95±2.91*	83.33±1.47*	4.46±0.05	0.38±0.10**	2.34±0.03**	0.57±0.05**	0.18±0.02*
LTA100	3471.60±83.81##	233.70±13.17#	103.38±4.23##	4.36±0.09	0.49±0.13#	2.54±0.05#	0.49±0.06#	0.17±0.01
LTA300	3611.36±64.92##	267.59±12.95##	115.12±2.07##	4.07±0.12	0.51±0.08#	2.59±0.06#	0.51±0.02	0.16±0.02
LTA500	3537.76±48.31##	215.49±2.32#	112.44±0.91##	4.29±0.08	0.45±0.05#	2.56±0.01#	0.46±0.01#	0.14±0.02

629

630

631

632

633

634

635 Table 5 Effects of L-theanine on the intestinal morphology of rats under dietary fiber feeding (n=10)

636

Group	Duodenum			Jejunum			Ileum		
	height of villi(μm)	crypt depth (μm)	V/C	height of villi(μm)	crypt depth (μm)	V/C	height of villi(μm)	crypt depth (μm)	V/C
Control A	0.35±0.02	0.10±0.01	3.39±0.37	0.33±0.01	0.11±0.01	2.53±0.49	0.48±0.01	0.13±0.00	3.49±0.17
Control B	0.37±0.01	0.12±0.02	3.23±0.26	0.43±0.01**	0.14±0.02	3.19±0.39	0.55±0.01	0.14±0.01	3.92±0.39
LTA100	0.41±0.03	0.13±0.02	3.08±0.44	0.44±0.01	0.15±0.01	4.08±0.76	0.57±0.04	0.16±0.01	3.57±0.52
LTA300	0.43±0.01	0.14±0.01	3.14±0.18	0.49±0.07	0.14±0.01	3.56±0.39	0.60±0.02	0.17±0.00#	3.51±0.03
LTA500	0.53±0.03##	0.15±0.01#	3.52±0.27	0.53±0.03#	0.13±0.02	4.19±0.55	0.63±0.03	0.18±0.00##	3.58±0.08




Fig. 1 Effects of LTA on the protein expression of ACC1 (A), FASN (B), HMGCR (C), LDLR (D), SREBP-1C (E) and SREBP-2 (F) in the liver, as well as the effect on the protein expression of GLUT2 (G), PCK1 (H), SGLT1 (I), G6PC (J), PFKM (K) and p-GSK-3 β (L) in colon under dietary fiber feeding in rats.





Fig. 2 Effects of LTA on duodenum, jejunum and ileum intestinal morphology sections of rats. A) duodenum; B) jejunum; C) ileum; 1) Control A; 2) Control B; 3) LTA100 ; 4) LTA300; 5) LTA500.

A table of contents entry:



LTA regulates SCFA metabolism and improves intestinal mucosal immunity by improving cholesterol synthesis in liver and inhibiting gluconeogenesis in colon.